Abstract: A transgenic mouse whose genome comprises the H/K-ras 4B chimeric gene to form a mammary tumor and, particularly, the expression vector producing H/K-Ras 4B chimeric protein by using MMTV (mouse mammary tumor virus) promoter. This protein contains the first 164 amino acids of the H-Ras followed by the last 24 amino acids of K-Ras 4B. The second, it relates to the transgenic mouse expressing the H/K-Ras 4B protein with a mammary tumor, and the third, the method of preparation.

Abstract: The present invention relates to halogen-free flameproof thermopolastic molding compounds which comprise an aromatic polycarbonate, a styrene-containing copolymer, a styrene-containing graft polymer, a phosphorus compound, a silicon compound, and a tetrafluoroethylene polymer. It has been found that the use of a specific type of silicon compound leads to a polymer mixture having improved stress crack resistance and impact properties. The silicon compound is represented as the following Formula (I). in which n and m have a value of from 5 to 8, and x and y have a value of from 1 to 5.

Abstract: Disclosed is a method of producing a carrier catalyst for a use in acrolein oxidation reaction. Metallic salt components of the catalyst including molybdate, vanadate and tungstate are dissolved in water. An additional metallic salt component of the catalyst is added to the aqueous solution of the salts to form a suspension of the catalyst. In the suspension, the total weight of water is about 0.8 to about 5 times of the total weight of the metallic salts in the catalyst. This method of preparing suspension minimizes the amount of water required to dissolve the metallic salts, which reduces the amount of time and energy to be used in evaporating water from the suspension in the following step of obtaining catalyst. Additionally, in obtaining catalyst from the suspension prepared by this method, it is possible to avoid the deterioration of the catalytic performance since less heat is required to evaporate the water. Disclosed also is a method of producing a carrier-retained catalyst.

Abstract: The present invention relates to a novel 1,3-diphenylpropane derivative having an inhibitory activity against tyrosinase represented by the following formula (I): ##STR1## in which - - represents double or single bond,R.sub.1 represents hydrogen or C.sub.1 -C.sub.10 alkyl,R.sub.2 represents C.sub.1 -C.sub.5 alkyl or C.sub.1 -C.sub.5 alkoxyalkyl, orR.sub.1 and R.sub.2 together represent a 5 to 6 membered heterocycle which can be substituted by C.sub.1 -C.sub.5 alkyl and which contains oxygen as the hetero atom,R.sub.3 represents hydrogen or C.sub.1 -C.sub.7 alkyl,R.sub.4 represents hydrogen, hydroxy, or oxo, andR.sub.5 and R.sub.6 mindependently of one another represent hydrogen or C.sub.1 -C.sub.5 alkyl.

Abstract: The present invention provides a composition for preventing or treating periodontal diseases comprising an extract of Achyranthis radix, Ulmus cortex or a mixture thereof which inhibits the productions of superoxide, prostaglandin, and interleukin (IL-1.beta.) which are inducers for periodontal diseases and inhibits the enzyme activity of collagenase which decomposes collagen protein which is a substrate for the periodontal tissues, and at the same time promotes collagen protein synthesis, thereby treating periodontal diseases efficiently.

Abstract: Disclosed is a splice closure for telecommunications cables. The splice closure includes a body having an upper portion and a lower portion, at least one entrance hole formed at opposing ends of the body, a plurality of flanges formed longitudinally along edges of both the upper and lower portions of the body where the same are joined, a compound reservoir formed between the flanges and into which a sealing compound is injected to form a seal, end stoppers having at least one cable hole and which are provided at ends of the splice closure, and plugs received in the cable holes of the end stoppers.

Abstract: The present invention relates to a novel selective thrombin inhibitor having the following formula (I), which is also effective by oral administration: ##STR1## in which R.sup.1 represents acetyl substituted with aryl or aryloxy, or represents sulfonyl substituted with substituted or unsubstituted aryl or N-containing heterocyclic group,X represents a group of formula ##STR2## R.sup.2 and R.sup.3 independently of one another represent hydrogen; cycloalkyl substituted or unsubstituted with carboxyl or alkoxycarbonyl; arylalkyloxy; hydroxy; or lower alkyl substituted or unsubstituted with carboxyl, alkoxycarbonyl or hydroxy, orR.sup.2 and R.sup.3 together with nitrogen atom to which they are attached can form a piperidine group substituted with carboxyl or alkoxycarbonyl,R.sup.4 represents hydrogen, lower alkyl or lower alkoxy,R.sup.

Abstract: The present invention relates to a novel selective thrombin inhibitor having the following formula (I), which is also effective by oral administration: ##STR1## in which R.sup.1 represents acetyl substituted with aryl or aryloxy, or represents sulfonyl substituted with substituted or unsubstituted aryl or N-containing heterocyclic group,x represents a group of formula ##STR2## R.sup.2 and R.sup.3 independently of one another represent hydrogen; cycloalkyl substituted or unsubstituted with carboxyl or alkoxycarbonyl; arylalkyloxy; hydroxy; or lower alkyl substituted or unsubstituted with carboxyl, alkoxycarbonyl or hydroxy, orR.sup.2 and R.sup.3 together with nitrogen atom to which they are attached can form a piperidine group substituted with carboxyl or alkoxycarbonyl,R.sup.4 represents hydrogen, lower alkyl or lower alkoxy,R.sup.

Abstract: The present invention relates to a novel quinolone compound having an excellent antibacterial activity. More specifically, the present invention relates to 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4 -oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid represent by the following formula: ##STR1## or its isomer.

Abstract: A human embryonic lung fibroblast diploid cell strain LBHEL(KCTC 0127BP) is highly susceptible to varicella zoster virus(VZV). A cell-free varicella zoster virus (VZV) is produced by (a) culturing the human embryonic lung fibroblast diploid cell strain LBHEL(KCTC 0127BP) of claim 1 in a culture vessel to give cultured LBHEL cells; (b) infecting the cultured LBHEL cells with VZV to give VZV-infected cells; (c) culturing and harvesting the VZV-infected cells; (d) disrupting the harvested cells to obtain a cell homogenate; and (e) centrifuging the cell homogenate to obtain a supernatant containing the cell-free VZV.

Abstract: A cable splice closure assembly includes an end cap body having at least one cable passage hole therein for the passage of a cable therethrough, the end cap body defining a seal zone for retaining a sealing material and a thread zone, and a screw plug having a cable passage hole therein for the passage of a cable therethrough, the screw plug being adapted for mating engagement with the thread zone of the end cap body.

Abstract: A monoclonal antibody specific for human 4-1BB, accessory molecule, selectively expressed on activated T cells; polynucleotides encoding the variable regions of the monoclonal antibody and amino acid sequences deduced therefrom; a hybridoma cell line producing the monoclonal antibody; and a process for preparing the hybridoma cell line.

Abstract: A peptide consisting of the following amino acid sequence, or an analogue or a fragment thereof, has an inhibitory activity on cholesteryl ester transfer protein:Glu Asp Thr Ser Pro Glu Asp Lys Met Gln Asp Tyr Val Lys Gln Ala Thr Arg Thr Ala Gln Asp Ala Leu Thr Ser Val Lys.

Abstract: The present invention relates to a novel quinolone compound having an excellent antibacterial activity. More specifically, the present invention relates to 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4 -oxo-1,4-dihydro-1,8-naphthyridine -3-carboxylic acid represent by the following formula: ##STR1## or its isomer.

Abstract: A process for preparing a deodorized resin for a dry toner which comprises: (a) polymerizing an aromatic vinylic monomer and an acrylic monomer in the presence of a molecular weight-controlling agent, an initiator and an emulsifier using a two-step emulsion polymerization process to obtain a latex having a bimodal molecular weight distribution; and (b) treating the latex with an oil-soluble peroxide.

Abstract: The present invention relates to a novel polymeric ultraviolet(UV) screening agent comprising at least one monomer represented by the following formula (I) in the molecule: ##STR1## in which X represents the following formula (II) or (III), ##STR2## wherein R represents C.sub.1 -C.sub.12 alkyl or C.sub.3 -C.sub.12 cycloalkyl which can be optionally substituted by C.sub.1 -C.sub.6 alkyl, and to a process for preparing the same.

Abstract: The present invention relates to a novel quinolone compound having an excellent antibacterial activity. More specifically the present invention relates to a novel quinoline(naphthyridine)carboxylic acid derivative represented by the following formula (I), which has an 4-aminomethyl-3-oximepyrrolidine substituent on 7-position of the quinolone nucleus and shows a superior antibacterial activity in contrast to the known quinolone antibactrial agents having a weak activity against gram-positive bacterial strains and also has a broad antibacterial spectrum and a highly improved pharmacokinetic property ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and Q are defined as described in the specification.

Abstract: A novel saponin component having a molecular weight of about 956 daltons, a process for isolating the saponin component from the bark of Quillaja saponaria Molina, a vaccine formulation comprising the saponin component as an immune adjuvant, a method for increasing the immune response to an antigen by employing an adjuvant composition comprising saponin component and a second adjuvant.

Abstract: The present invention relates to a composition for enhancing oral hygiene which can effectively prevent and treat periodontal diseases and dental caries, characterized in that it contains as an effective component one or more component selected from ursodesoxycholic acid and chenodesoxycholic acid having a good inhibiting effect on collagenase, which is known as the inducer of gingivitis.

Abstract: An ophthalmic formulation for treating myopia, which comprises a dopamine agonist and cyclodextrin or its derivative in combination with a pharmaceutically acceptable carrier.